{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T08:20:00Z","timestamp":1783153200408,"version":"3.54.6"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T00:00:00Z","timestamp":1777766400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82472266"],"award-info":[{"award-number":["82472266"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002799","name":"Capital Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002799","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017962","name":"Jiangsu Commission of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017962","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.ejps.2026.107544","type":"journal-article","created":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T21:01:10Z","timestamp":1777842070000},"page":"107544","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Exposure\u2013response modeling of QTc interval and creatine kinase-MB in healthy people and treatment-na\u00efve adults living with HIV-1 treated with ainuovirine monotherapy or combined with lamivudine and tenofovir DF"],"prefix":"10.1016","volume":"222","author":[{"given":"Ziyue","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinming","family":"Yun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1927-0081","authenticated-orcid":false,"given":"Hong","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ejps.2026.107544_bib0001","doi-asserted-by":"crossref","first-page":"397","DOI":"10.3851\/IMP2920","article-title":"Safety, tolerability and pharmacokinetics of doravirine, a novel HIV non-nucleoside reverse transcriptase inhibitor, after single and multiple doses in healthy subjects","volume":"20","author":"Anderson","year":"2015","journal-title":"Antivir. Ther."},{"issue":"1","key":"10.1016\/j.ejps.2026.107544_bib0002","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-79808-y","article-title":"QTc interval prolongation and its associated factors among HIV infected patients on ART in Mettu Town","volume":"14","author":"Befkadu","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejps.2026.107544_bib0003","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.2147\/DDDT.S65596","article-title":"Pharmacokinetics and tolerability of the new second-generation nonnucleoside reverse- transcriptase inhibitor KM-023 in healthy subjects","volume":"8","author":"Cha","year":"2014","journal-title":"Drug Des. Devel. Ther."},{"issue":"6","key":"10.1016\/j.ejps.2026.107544_bib0005","doi-asserted-by":"crossref","first-page":"459","DOI":"10.3851\/IMP3335","article-title":"Abnormal QTc syndrome in HIV-infected patients: a systematic review of prevalence and risk factors","volume":"24","author":"Chastain","year":"2019","journal-title":"Antivir. Ther."},{"issue":"26","key":"10.1016\/j.ejps.2026.107544_bib0006","article-title":"Risk of elevation of serum creatine kinase among HIV-positive individuals receiving dolutegravir-based combination antiretroviral therapy","volume":"98","author":"Chen","year":"2019","journal-title":"Med. (Baltim.)"},{"issue":"6","key":"10.1016\/j.ejps.2026.107544_bib0007","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.jinf.2006.11.001","article-title":"Role of antiretroviral treatment in prolonging QTc interval in HIV-positive patients","volume":"54","author":"Chinello","year":"2007","journal-title":"J. Infect."},{"issue":"7","key":"10.1016\/j.ejps.2026.107544_bib0008","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1002\/jcph.2025","article-title":"Drug-Drug interactions in people living with HIV at risk of hepatic and renal impairment: current status and future perspectives","volume":"62","author":"Cottura","year":"2022","journal-title":"J. Clin. Pharmacol."},{"issue":"7","key":"10.1016\/j.ejps.2026.107544_bib0009","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S1473-3099(20)30770-2","article-title":"QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial","volume":"21","author":"Dooley","year":"2021","journal-title":"Lancet Infect. Dis."},{"issue":"1","key":"10.1016\/j.ejps.2026.107544_bib0010","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s10928-024-09948-1","article-title":"No QT interval prolongation effect of sepiapterin: a concentration-QTc analysis of pooled data from phase 1 and phase 3 studies in healthy volunteers and patients with phenylketonuria","volume":"52","author":"Gao","year":"2025","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"issue":"3","key":"10.1016\/j.ejps.2026.107544_bib0011","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s10928-017-9558-5","article-title":"Scientific white paper on concentration-QTc modeling","volume":"45","author":"Garnett","year":"2018","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"issue":"20","key":"10.1016\/j.ejps.2026.107544_bib0012","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1097\/CM9.0000000000002917","article-title":"Population pharmacokinetics of Ainuovirine and exposure-response analysis in human immunodeficiency virus-infected individuals","volume":"137","author":"Han","year":"2024","journal-title":"Chin. Med. J. (Engl.)"},{"issue":"5","key":"10.1016\/j.ejps.2026.107544_bib0013","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01219-22","article-title":"No meaningful drug-drug interactions are associated with the coadministration of ACC007, Lamivudine, and Tenofovir disoproxil fumarate","volume":"67","author":"Hao","year":"2023","journal-title":"Antimicrob. Agent. Chemother."},{"issue":"3","key":"10.1016\/j.ejps.2026.107544_bib0014","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1161\/CIRCULATIONAHA.119.043042","article-title":"HIV infection is associated with variability in ventricular repolarization: the Multicenter AIDS cohort study (MACS)","volume":"141","author":"Heravi","year":"2020","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.ejps.2026.107544_bib0015","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/cpdd.1309","article-title":"Pharmacokinetic and bioequivalence evaluation of single-tablet and separate-tablet regimens for ainuovirine, Lamivudine, and tenofovir disoproxil fumarate in Chinese healthy subjects","volume":"13","author":"Huang","year":"2024","journal-title":"Clin. Pharmacol. Drug Dev."},{"issue":"10","key":"10.1016\/j.ejps.2026.107544_bib0016","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1007\/s40261-017-0552-x","article-title":"A randomized trial to assess the effect of Doravirine on the QTc interval using a single supratherapeutic dose in healthy adult volunteers","volume":"37","author":"Khalilieh","year":"2017","journal-title":"Clin. Drug Investig."},{"issue":"1","key":"10.1016\/j.ejps.2026.107544_bib0017","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-00290-x","article-title":"De novo electrocardiographic abnormalities in persons living with HIV","volume":"11","author":"Knudsen","year":"2021","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.ejps.2026.107544_bib0018","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s10928-018-9582-0","article-title":"Assessing QT\/QTc interval prolongation with concentration-QT modeling for phase I studies: impact of computational platforms, model structures and confidence interval calculation methods","volume":"45","author":"Lu","year":"2018","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"issue":"3","key":"10.1016\/j.ejps.2026.107544_bib0019","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ijantimicag.2014.10.013","article-title":"Muscle symptoms and creatine phosphokinase elevations in patients receiving raltegravir in clinical practice: results from the SCOLTA project long-term surveillance","volume":"45","author":"Madeddu","year":"2015","journal-title":"Int. J. Antimicrob. Agent."},{"issue":"6","key":"10.1016\/j.ejps.2026.107544_bib0020","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1093\/cid\/ciac873","article-title":"Prolonged QTc in black and latinx cisgender and transgender women with Human immunodeficiency virus in an urban area","volume":"76","author":"Malangu","year":"2023","journal-title":"Clin. Infect. Dis."},{"issue":"4","key":"10.1016\/j.ejps.2026.107544_bib0021","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1080\/00498254.2018.1451667","article-title":"Characterisation of the absorption, distribution, metabolism, excretion and mass balance of doravirine, a non-nucleoside reverse transcriptase inhibitor in humans","volume":"49","author":"Sanchez","year":"2019","journal-title":"Xenobiotica"},{"key":"10.1016\/j.ejps.2026.107544_bib0022","volume":"36","author":"Su","year":"2023","journal-title":"Lancet Reg. Health West Pac."},{"key":"10.1016\/j.ejps.2026.107544_bib0023","volume":"90","author":"Su","year":"2024","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2026.107544_bib0024","article-title":"Single-ascending dose and food effect studies to assess safety and pharmacokinetics of ainuovirine, a novel non-nucleoside reverse transcriptase inhibitor, for treatment of HIV-1 infection","volume":"90","author":"Su","year":"2024","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2026.107544_bib0025","article-title":"Safety, pharmacokinetics and antiviral activity of ainuovirine as 10-day monotherapy in treatment-na\u00efve adults with HIV-1","volume":"90","author":"Su","year":"2024","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"15","key":"10.1016\/j.ejps.2026.107544_bib0026","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1097\/QAD.0000000000003358","article-title":"Higher prevalence of QTc interval prolongation among virologically suppressed older people with HIV","volume":"36","author":"Theerasuwipakorn","year":"2022","journal-title":"AIDS"},{"issue":"24","key":"10.1016\/j.ejps.2026.107544_bib0027","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1056\/NEJMoa1914279","article-title":"Sudden cardiac death and myocardial fibrosis, determined by autopsy, in persons with HIV","volume":"384","author":"Tseng","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejps.2026.107544_bib0028","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1093\/ofid\/ofae631.1444","article-title":"Safety and pharmacokinetics of Ainuovirine, a novel non-nucleoside reverse transcriptase inhibitor, in healthy Chinese adults","volume":"12","author":"Wu","year":"2025","journal-title":"Open. Forum. Infect. Dis."},{"key":"10.1016\/j.ejps.2026.107544_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2026.107471","article-title":"Absorption, distribution, metabolism, excretion and mass balance of ainuovirine, a non-nucleoside reverse transcriptase inhibitor in humans","volume":"220","author":"Wu","year":"2026","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2026.107544_bib0030","volume":"49","author":"Zhang","year":"2024","journal-title":"Lancet Reg. Health West Pac."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098726001181?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098726001181?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T08:00:59Z","timestamp":1783152059000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098726001181"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":29,"alternative-id":["S0928098726001181"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2026.107544","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exposure\u2013response modeling of QTc interval and creatine kinase-MB in healthy people and treatment-na\u00efve adults living with HIV-1 treated with ainuovirine monotherapy or combined with lamivudine and tenofovir DF","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2026.107544","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107544"}}